Neuromodulation and Cognitive Training for Substance Use Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Minnesota
About this trial
The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.
Eligibility criteria
Qualifiers
Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
Able to provide written consent and comply with study procedures.
Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).
Disqualifiers
Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
Over 9 months of abstinence from substance use
A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
Presence of a condition that would render study measures difficult or impossible to administer or interpret
Trial design
Treatments tested in this trial
- tDCS
- Cognitive Training
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov